12/04/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
2:10 PM | Cormorant Asset Management, LP (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/12/2024
1:31 PM | EyePoint Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/12/2024
8:33 AM | Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/07/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/06/2024
7:54 AM | EyePoint Pharmaceuticals (Subject)
FEDERATED HERMES, INC. (Filed by)
FEDERATED HERMES, INC. (Filed by)
| Form SC 13G | |
11/04/2024
10:57 AM | EyePoint Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
|
10/31/2024
3:16 PM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/31/2024
11:51 AM | EyePoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SCHEDULE 13G/A | |
10/30/2024
3:20 PM | EyePoint Pharmaceuticals (Filer)
| Form 424B5 | |
10/28/2024
4:17 PM | EyePoint Pharmaceuticals (Filer)
| Form 424B5 | |
10/28/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/24/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/23/2024
3:34 PM | ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/22/2024
2:24 PM | BlackRock, Inc. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G | |
10/15/2024
10:58 AM | EyePoint Pharmaceuticals (Subject)
GUYER DAVID R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/05/2024
3:02 PM | EyePoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2024
3:02 PM | EyePoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/04/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/21/2024
3:32 PM | DICICCO WENDY F (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/18/2024
11:15 PM | EyePoint Pharmaceuticals (Filer)
| Form EFFECT | |
08/08/2024
3:42 PM | EyePoint Pharmaceuticals (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
08/08/2024
3:46 PM | EyePoint Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
08/07/2024
6:00 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/26/2024
3:47 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
3:24 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:00 PM | EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:03 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:04 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/26/2024
8:25 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/25/2024
3:16 PM | ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/21/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/04/2024
3:28 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/28/2024
3:22 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/28/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/16/2024
4:19 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/14/2024
3:39 PM | EyePoint Pharmaceuticals (Subject)
GUYER DAVID R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/09/2024
9:12 AM | EyePoint Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/08/2024
3:23 PM | Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/08/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/06/2024
8:25 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Will the Nasdaq 100 crash? (Ad) In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio…
And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once…
My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time.
Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place…
While I cannot promise future returns or against losses…
This strategy targets major payouts OVERNIGHT! Click here to get the details. |
05/01/2024
4:08 PM | Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
04/30/2024
7:53 PM | Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G | |
04/22/2024
3:15 PM | Adage Capital Management, L.P. (Reporting)
Atchinson Robert (Reporting)
EyePoint Pharmaceuticals (Issuer)
Gross Phillip (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
04/02/2024
4:27 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/08/2024
12:53 PM | EyePoint Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/07/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/04/2024
4:37 PM | EyePoint Pharmaceuticals (Issuer)
Ribeiro Ramiro (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/04/2024
4:40 PM | EyePoint Pharmaceuticals (Issuer)
Ribeiro Ramiro (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
6:01 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/14/2024
8:08 PM | EyePoint Pharmaceuticals (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
02/13/2024
4:37 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:38 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:38 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:39 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:40 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
11:00 AM | EyePoint Pharmaceuticals (Subject)
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)
| Form SC 13G/A | |
02/07/2024
6:54 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/06/2024
9:55 AM | EyePoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SC 13G/A | |
02/05/2024
4:15 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
3:22 PM | EyePoint Pharmaceuticals (Subject)
Jones David Scott (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/30/2024
3:53 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/29/2024
4:51 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/29/2024
4:54 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/25/2024
5:24 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/25/2024
5:26 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/24/2024
3:50 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/24/2024
3:25 PM | EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/23/2024
3:42 PM | EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/23/2024
3:19 PM | EyePoint Pharmaceuticals (Subject)
Paggiarino Dario A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/22/2024
3:19 PM | EyePoint Pharmaceuticals (Subject)
Jones David Scott (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/16/2024
5:55 PM | EyePoint Pharmaceuticals (Issuer)
Ocumension Therapeutics (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/16/2024
5:01 PM | EyePoint Pharmaceuticals (Issuer)
Liu Ye (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/11/2024
4:33 PM | EyePoint Pharmaceuticals (Subject)
Ocumension Therapeutics (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2024
3:53 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/10/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/09/2024
8:28 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:17 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:53 PM | ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:53 PM | ANDO GORAN (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:54 PM | DICICCO WENDY F (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:54 PM | Duty Stuart (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:55 PM | EyePoint Pharmaceuticals (Issuer)
Landis John B. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:56 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:04 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:07 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:09 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:11 PM | EyePoint Pharmaceuticals (Issuer)
Pine Michael Craig (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:12 PM | EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2024
5:37 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4/A | |
01/02/2024
4:41 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad) All of our key indicators are flashing the same signal: an altcoin season is fast approaching.
And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin |
Free EYPT Stock Alerts